Skip to main content

mTOR Inhibition for Cancer Therapy: Past, Present and Future

  • Book
  • © 2016

Overview

  • First book on that topic
  • Input and perspectives by international leaders?
  • Preclinical and clinical data available on the subject have been integrated
  • A dedicated chapter on toxicity profile of mTOR inhibitors
  • Future directions for the development of mTOR inhibitors

This is a preview of subscription content, log in via an institution to check access.

Access this book

eBook USD 16.99 USD 79.99
Discount applied Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

About this book

This book describes the challenges involved in developing mTOR inhibitors for cancer treatment, starting with an in-depth examination of their molecular mechanism of action, with emphasis on the class side-effects, efficacy and mechanisms of resistance, as well as on promising novel directions for their development, including novel compounds and rational combinations with other anti-neoplastic drugs. 

Over the last 10 years, inhibitors of mTOR have emerged as a major class of anticancer drugs. Two rapamycin analogs are currently approved for the treatment of renal cell carcinoma, and it is estimated that a variety of other tumor types could benefit from mTOR inhibition, with numerous clinical trials (including pivotal registration trials) already underway. Second-generation small-molecule inhibitors of the pathway have also shown promise in terms of their superior tolerability and efficacy and are undergoing extensive clinical evaluation, with an estimated 30+ compoundscurrently under evaluation.

Similar content being viewed by others

Keywords

Table of contents (13 chapters)

Editors and Affiliations

  • Samuel Oschin Comprehensive Cancer Inst Cedars Sinai Medical Center, Los Angeles, USA

    Monica Mita

  • Samuel Oschin Comprehensive Cancer Inst Cedars-Sinai Medical Center, Los Angeles, USA

    Alain Mita

  • Stemline Therapeutics, Inc., New York, USA

    Eric K. Rowinsky

About the editors

Monica Mita and Alain Mita are Associate Professors of Medicine and Co-Directors of the Experimental Therapeutics Program at the Samuel Oschin Comprehensive Cancer institute, Cedars-Sinai Medical Center in Los Angeles, CA. Eric Rowinsky is Chief Medical Officer, Head of Research and Development, and Executive Vice President at Stemline Therapeutics, Inc. He is also an Adjunct Professor of Medicine at New York University School of Medicine and a cancer drug development consultant at Oncodrugs.

Bibliographic Information

  • Book Title: mTOR Inhibition for Cancer Therapy: Past, Present and Future

  • Editors: Monica Mita, Alain Mita, Eric K. Rowinsky

  • DOI: https://doi.org/10.1007/978-2-8178-0492-7

  • Publisher: Springer Paris

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Springer-Verlag France 2016

  • Hardcover ISBN: 978-2-8178-0491-0Published: 01 December 2015

  • Softcover ISBN: 978-2-8178-0557-3Published: 23 August 2016

  • eBook ISBN: 978-2-8178-0492-7Published: 18 November 2015

  • Edition Number: 1

  • Number of Pages: VI, 300

  • Topics: Oncology, Hematology, Molecular Medicine

Publish with us